Cerebral Adrenoleukodystrophy (CALD) Global Market Report 2025

The cerebral adrenoleukodystrophy (CALD) market size has grown rapidly in recent years. It will grow from $6.58 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth during the historic period can be attributed to increased awareness of rare diseases, the expansion of newborn screening programs, a growing focus on neurodegenerative disorders, the introduction of Lorenzo’s oil, advancements in research on peroxisomal disorders, advocacy by patient support groups, and improvements in healthcare infrastructure.

The cerebral adrenoleukodystrophy (CALD) market size is expected to see rapid growth in the next few years. It will grow to $13.05 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The projected growth in the forecast period is driven by the emergence of gene therapy solutions, the expansion of newborn screening technologies, the development of targeted drug delivery systems, increasing investment in rare disease research, the rising adoption of digital health tools, a growing demand for personalized treatments, collaborations between biotech and pharmaceutical companies, and enhanced awareness through global advocacy campaigns. Key trends include gene editing with CRISPR, AI-powered diagnostic algorithms, advanced neuroimaging techniques, next-generation sequencing advancements, brain-targeted nanomedicine, wearable devices for neurological monitoring, digital twin simulations for treatment planning, cloud-based genomic data sharing, virtual reality for caregiver training, and blockchain for secure patient data management.

The increase in healthcare spending is expected to drive the growth of the cerebral adrenoleukodystrophy (CALD) market. Healthcare expenditures continue to rise due to aging populations, the prevalence of chronic diseases, advancements in medical treatments, rising drug costs, and expanded health coverage. Increased healthcare funding supports the development of diagnostic tools, innovative treatments such as gene therapy and stem cell transplantation, and improved patient access to specialized care and early intervention for CALD. For example, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, reported that national health expenditures (NHE) grew by 7.5% in 2023, surpassing the gross domestic product (GDP) growth rate of 6.1%. Over the next decade, from 2023 to 2032, NHE is projected to grow at an average annual rate of 5.6%, increasing healthcare spending as a share of GDP from 17.3% in 2022 to 19.7% in 2032. This continued increase in healthcare spending is driving the expansion of the CALD market.

Companies in the cerebral adrenoleukodystrophy (CALD) market are focusing on regulatory approvals to drive medical breakthroughs and develop innovative therapies, such as gene therapies, to halt disease progression, improve patient outcomes, and potentially provide curative treatments for this rare and life-threatening disorder. Gene therapy involves modifying or replacing faulty genes within a patient’s cells to treat or cure diseases. For example, in September 2022, Bluebird Bio Inc., a US-based biotechnology company, received accelerated approval from the United States Food and Drug Administration (FDA) for Skysona (elivaldogene autotemcel) to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active cerebral adrenoleukodystrophy (CALD). Skysona is a one-time gene therapy that employs ex vivo transduction with the Lenti-D lentiviral vector (LVV) to introduce functional copies of the ABCD1 gene into a patient’s hematopoietic stem cells (HSCs). This newly introduced gene enables the production of the ALD protein (ALDP), which aids in breaking down very long-chain fatty acids (VLCFAs), potentially slowing or preventing further inflammation and demyelination.

In November 2022, Minoryx Therapeutics, a Spain-based biotechnology company, partnered with Neuraxpharm Group under a license agreement for the commercialization of leriglitazone in Europe. Under the agreement, Minoryx granted Neuraxpharm exclusive European rights to leriglitazone, which is currently under review by the European Medicines Agency (EMA) for the treatment of X-linked adrenoleukodystrophy (X-ALD). Neuraxpharm Group, a Germany-based pharmaceutical company, specializes in treating central nervous system (CNS) disorders, including cerebral adrenoleukodystrophy, expanding treatment options for patients across Europe.

Major players in the cerebral adrenoleukodystrophy (cald) market are Pfizer Inc., Sanofi S.A., Novartis AG, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Poxel S.A., Neuraxpharm Group, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Calico Life Sciences, Magenta Therapeutics Inc., SOM Biotech, Minoryx Therapeutics S.L., NeuroVia Inc., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., Bluebird Bio Inc., Orpheris Inc., Sperogenix Therapeutics, Abliva.

North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2024. The regions covered in cerebral adrenoleukodystrophy (CALD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cerebral adrenoleukodystrophy (CALD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cerebral adrenoleukodystrophy (CALD) is a rare, progressive neurological disorder primarily affecting males, caused by mutations in the **ABCD1** gene. It is characterized by the accumulation of very long-chain fatty acids in the brain, leading to the destruction of myelin, the protective covering of nerve cells. CALD is a form of adrenoleukodystrophy (ALD) that affects the brain and spinal cord, resulting in symptoms such as cognitive decline, behavioral changes, and motor dysfunction.

The primary treatment approaches for CALD include dietary management, medications, and stem cell therapy. Dietary management focuses on modifying the patient's diet to help control symptoms. The condition affects various patient age groups, including adults, children, infants, and teens, while key end users include healthcare facilities, patients and caregivers, and pharmaceutical companies.

The cerebral adrenoleukodystrophy market research report is one of a series of new reports that provides cerebral adrenoleukodystrophy market statistics, including cerebral adrenoleukodystrophy industry global market size, regional shares, competitors with an cerebral adrenoleukodystrophy market share, detailed cerebral adrenoleukodystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral adrenoleukodystrophy industry. This cerebral adrenoleukodystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cerebral adrenoleukodystrophy (CALD) market consists of revenues earned by entities by providing services such as genetic testing, diagnostic imaging, medical consultations, hematopoietic stem cell transplantation, patient monitoring, counseling and long-term care management for individuals affected by cerebral adrenoleukodystrophy (CALD). The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral adrenoleukodystrophy (CALD) market also includes sales of gene therapies, corticosteroids and supportive care treatments aimed at managing symptoms and slowing disease progression. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.